Sign in
CompletedPhase 1

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Key facts

Who runs it
Longbio Pharma
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
60 people enrolled
Started
13 Jul 2022
Ended
4 Mar 2024
Type of study
Interventional, 10 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LP-003 Dose 1 (Single)
  • LP-003 Dose 2 (Single)
  • LP-003 Dose 3 (Single)
  • LP-003 Dose 4 (Single)
  • LP-003 Dose 5 (Single)
  • Placebo (Single)
  • LP-003 Dose 6 (Multiple)
  • LP-003 Dose 7 (Multiple)
  • LP-003 Dose 8 (Multiple)
  • Placebo (Multiple)
Record updated
12 December 2025

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Healthy males or females aged 18 through 50 years
  • Male subjects must weigh ≥50 kg, and female subjects must weigh ≥45 kg, with a BMI between 19.0 and 28.0 kg/m² (inclusive)
  • Male subjects and their partners or female subjects must agree to use one or more non-pharmaceutical contraceptive methods (such as total abstinence, condoms, Iuds, partner ligation, etc.) during the trial period and for 6 months after the trial, and do not plan to donate sperm or eggs
  • The subjects fully understand the purpose, nature, method and possible adverse reactions of the experiment, and voluntarily participate in the experiment and sign the informed consent
  • The subjects were able to communicate well with the researchers and complete the study according to the protocol

Who cannot take part

  • Patients who had undergone surgery within 3 months before the trial that the researchers judged would affect drug absorption, distribution, metabolism, and excretion, or had surgery within 4 weeks prior to the trial, or planned to have surgery during the study period
  • Any history of infection within 14 days prior to administration
  • A person who is currently infected with parasites or has traveled to an endemic area within the last 3 months or 24 weeks prior to administration
  • Patients who have received any biological agent (including antibodies or derivatives such as omalizumab) within 16 weeks prior to administration (or 5 half-lives, selecting the longer time period)
  • Participants who had participated in other clinical trials within 3 months prior to screening
  • People who are allergic to the experimental drug and any of its excipients, have a history of allergy to monoclonal antibodies, and are allergic to multiple drugs and food
  • Patients who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other diseases that can interfere with the test results
  • Hepatitis B surface antigen, hepatitis C virus antibodies, human immunodeficiency virus antibodies, treponema pallidum antibodies A positive person
  • The investigator deems any condition unsuitable for study participation
  • Pregnant and lactating women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).

The 10 groups in the trial

  • Cohort 1: LP-003 Dose 1 (Single)Treatment being tested

    Treatment: LP-003 Dose 1 (Single)

  • Cohort 2: LP-003 Dose 2 (Single)Treatment being tested

    Treatment: LP-003 Dose 2 (Single)

  • Cohort 3: LP-003 Dose 3 (Single)Treatment being tested

    Treatment: LP-003 Dose 3 (Single)

  • Cohort 4: LP-003 Dose 4 (Single)Treatment being tested

    Treatment: LP-003 Dose 4 (Single)

  • Cohort 5: LP-003 Dose 5 (Single)Treatment being tested

    Treatment: LP-003 Dose 5 (Single)

  • Cohort 6: Placebo (Single)Placebo, for comparison

    Treatment: Placebo (Single)

  • Cohort 7: LP-003 Dose 6 (Multiple)Treatment being tested

    Treatment: LP-003 Dose 6 (Multiple)

  • Cohort 8: LP-003 Dose 7 (Multiple)Treatment being tested

    Treatment: LP-003 Dose 7 (Multiple)

  • Cohort 9: LP-003 Dose 8 (Multiple)Treatment being tested

    Treatment: LP-003 Dose 8 (Multiple)

  • Cohort 10: Placebo (Multiple)Placebo, for comparison

    Treatment: Placebo (Multiple)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-003 in Healthy Volunteers
Record updated
12 December 2025